epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove DTIC-Dome
    dacarbazine
  • remove ribavirin
    generic
  • remove Simlandi (adalimumab-ryvk)
    adalimumab

multicheck MultiCheck Results - 1 Interaction

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face DTIC-Dome (dacarbazine) + ribavirin (generic)

Monitor/Modify Tx


dacarbazine + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

Additional Considerations

Smiley face Smiley face adalimumab in Simlandi (adalimumab-ryvk)

caution advised with narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx with immune modulators may reverse this effect, resulting in altered levels of concomitant drugs

Smiley face Smiley face ribavirin

caution advised with narrow therapeutic index drugs extensively metabolized in the liver; viral eradication may improve hepatic metabolic function, decr. levels, efficacy of concomitant drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information